Ginkgo Bioworks Holdings, Inc. – DNA, DNA-WT
Investors Of Ginkgo Bioworks Who Have Suffered Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating whether Ginkgo Bioworks (“Ginkgo” or the “Company”) (NYSE: DNA) violated federal securities laws.
Ginkgo investors should be aware that Scorpion Capital issued a report on October 6, 2021 which, among other things, stated that “Ginkgo Bioworks is a colossal scam, a Frankenstein mash-up of the worst frauds of the last 20 years. At $23B market cap, it is rare to see a related-party scheme on Ginkgo’s scale in the US markets – it is, quite simply, the US version of the ‘China Hustle.’”
Scorpion Capital reported that it “. . . conducted an intensive investigation into Ginkgo’s business model and practices, with a particular focus on the related-party entities that drive the bulk of its revenue. [Scorpion Capital] completed 21 research interviews, encompassing a broad sample of former employees and executives of Ginkgo, as well as individuals who are currently employed at its related party ‘customers.’ [Scorpion Capital’s] research leads [Scorpion Capital] to conclude that Ginkgo is a house of cards – in [Scorpion Capital’s] opinion, one of the most brazen frauds of the last 20 years.”
The Scorpion Capital report further stated that “Ginkgo’s business model is based on a dubious shell game. The majority of its foundry revenue, an absurd 72% in 2020, and essentially 100% of its deferred revenue are derived from related-party ‘customers’ it created, funded, controls, or influences via its ownership position and board seats. Investments into these entities by Ginkgo and its largest investors are recycled back to Ginkgo and recorded as deferred or current revenue. The scheme reflects its woeful, decade-long failure to derive real revenue from third-party customers, forcing it to cover it up with a ploy that [Scorpion Capital] believe[s] to be enabled by its largest holders.”
On this news, shares of Ginkgo were down almost 17% during intraday trading on October 6, 2021, thereby injuring Ginkgo investors.